MediPharm Labs Sets Date to Release Fourth Quarter and Full Year 2018 Financial Results
27 Mars 2019 - 12:45PM
MediPharm Labs Corp. (TSXV: LABS) (OTCQB: MLCPF) (FSE:MLZ)
(“MediPharm Labs” or the “Company”) a global leader in specialized,
research-driven cannabis extraction, distillation, purification and
cannabinoid isolation, will release its fourth quarter and full
year financial results ended December 31, 2018 before markets open
on Wednesday, April 3, 2019.
About MediPharm Labs
Corp.Founded in 2015, MediPharm Labs has the distinction
of being the first company in Canada to become a licensed producer
for cannabis oil production under the ACMPR without first receiving
a cannabis cultivation licence. This expert focus on cannabis
concentrates from our cGMP (current Good Manufacturing Practices)
and ISO standard clean rooms and critical environments laboratory,
allows MediPharm Labs to produce purified, pharmaceutical-grade
cannabis oil and concentrates for advanced derivative products.
MediPharm Labs has invested in an expert, research-driven team,
state-of-the-art technology, downstream extraction methodologies
and purpose-built facilities to deliver pure, safe and
precisely-dosed cannabis products to patients and consumers.
MediPharm Labs’ private label program is a high margin business for
the Company, whereby it opportunistically procures dry cannabis
flower and trim from its numerous product supply partners, to
produce proprietary cannabis oil concentrate products for resale
globally on a private label basis.
Through its subsidiary, MediPharm Labs Australia
Pty. Ltd., MediPharm Labs has also completed its application
process with the federal Office of Drug Control to extract and
import medical cannabis products in Australia.
For further
information, please contact: |
Laura
Lepore, Vice President, Investor Relations &
Communications |
Telephone: |
705-719-7425 ext
216 |
Email: |
investors@medipharmlabs.com |
Website: |
www.medipharmlabs.com |
NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE
POLICIES OF THE TSXV) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
CAUTIONARY NOTE REGARDING
FORWARD-LOOKING INFORMATION:This news release contains
“forward-looking information” and “forward-looking statements”
(collectively, “forward-looking statements”) within the meaning of
the applicable Canadian securities legislation. All statements,
other than statements of historical fact, are forward-looking
statements and are based on expectations, estimates and projections
as at the date of this news release. Any statement that involves
discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, assumptions, future events or
performance (often but not always using phrases such as “expects”,
or “does not expect”, “is expected”, “anticipates” or “does not
anticipate”, “plans”, “budget”, “scheduled”, “forecasts”,
“estimates”, “believes” or “intends” or variations of such words
and phrases or stating that certain actions, events or results
“may” or “could”, “would”, “might” or “will” be taken to occur or
be achieved) are not statements of historical fact and may be
forward-looking statements. In this news release, forward-looking
statements relate to, among other things, expected GMP
certification and the establishment of operations in Australia.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable, are
subject to known and unknown risks, uncertainties, and other
factors which may cause the actual results and future events to
differ materially from those expressed or implied by such
forward-looking statements. Such factors include, but are not
limited to: general business, economic, competitive, political and
social uncertainties; the inability of MediPharm Labs to obtain
adequate financing; and the delay or failure to receive regulatory
approvals. There can be no assurance that such statements will
prove to be accurate, as actual results and future events could
differ materially from those anticipated in such statements.
Accordingly, readers should not place undue reliance on the
forward-looking statements and information contained in this news
release. Except as required by law, MediPharm Labs assumes no
obligation to update the forward-looking statements of beliefs,
opinions, projections, or other factors, should they change.
MediPharm Labs (TSXV:LABS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
MediPharm Labs (TSXV:LABS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024